PIPERONYL BUTOXIDE First draft prepared by A. Moretto Istituto di Medicina del Lavoro, Universita degli Studi di Padova, Padua, Italy Explanation Evaluation for acceptable daily intake Biochemical aspects Absorption, distribution, and excretion Effects on enzymes and other biochemical parameters Toxicological studies Acute toxicity Short-term toxicity Long-term toxicity and carcinogenicity Reproductive toxicity Developmental toxicity Genotoxicity Special studies Dermal and ocular irritation and dermal sensitization Studies with mixtures Observations in humans Comments Toxicological evaluation References Explanation Piperonyl butoxide was previously evaluated toxicologically by the JMPR in 1965, 1966, 1972, and 1992 (Annex I, references 3, 6, 18, and 65). An ADI of 0-0.03 mg/kg bw was allocated in 1972 on the basis of a one-year study in dogs. The 1992 JMPR confirmed the existing ADI and recommended that piperonyl butoxide be reviewed again in 1995 after submission of studies on acute toxicity and teratogenicity in rats, appropriate studies of genotoxicity, the results of an on-going one-year study in dogs, an on-going study of carcinogenicity in mice, and studies of carcinogenicity in rats and mice performed within the US National Toxicology Program, and observations in humans. Piperonyl butoxide was re-evaluated at the present Meeting within the periodic review programme of the CCPR, and a monograph summarizing all of the available data was prepared. Evaluation for acceptable daily intake 1. Biochemical aspects (a) Absorption, distribution, and excretion Male Swiss-Webster mice (18-20 g) were given piperonyl butoxide labelled with 14C at either the alpha-methylene or the alpha-carbon of the 2-(2-butoxyethoxy)ethoxymethyl side-chain by gavage at 1.7 mg (5 µmol)/kg bw. Radiocarbon was determined in expired carbon dioxide 0.5, 1, 2, 4, and 6 h and every 6 h up to 48 h after treatment, and in urine and faeces 12, 24, and 48 h after treatment. Two days after administration of [methylene-14C]-piperonyl butoxide, 97.2% of the radiolabel was recovered, with 75.5% in carbon dioxide, 6.1% in urine, 4% in faeces, and 6.8% in the carcass; after administration of piperonyl butoxide labelled in the 2(2-butoxyethoxy)ethoxymethyl side-chain, 75% of the radiolabel was recovered, with 65% in urine, 8% in faeces, and < 1% in carbon dioxide. In the latter case, the urinary metabolites were demethylated derivatives of the parent compound. Figure 1 shows the proposed metabolic pathway for piperonyl butoxide in mammals (Kamienski & Casida, 1970). In the same experiments, male Sprague-Dawley rats were given 3.4 mg (10 µmol)/kg bw labelled piperonyl butoxide by gavage. The total label (in expired carbon dioxide and urine) recovered at 48 h was 72-74%, and the pattern of excretion was similar to that observed in the mouse (Kamienski & Casida, 1970). Adult male Sprague-Dawley rats were given single intravenous doses of piperonyl butoxide labelled with 14C in the methylenedioxy or the alpha-methylene side-chain. Bile samples were collected from a fistula, and 10 urine samples were taken at various intervals before (one sample) and up to about 8 h after treatment; expired air was also collected. More than 10 metabolites were detected, but not identified, in urine and bile; the parent compound was identified only in fat (9-18% of the total radiolabel) and lung (15-25%) after about 8 h. After treatment with [14C-methylenedioxy]-piperonyl butoxide, about 40% of the label was recovered as carbon dioxide, < 1% in urine, and 3% in bile. After treatment with [14C-alpha-methylene]-piperonyl butoxide, 25-47% of the label was found in the bile and about 5% in urine; almost none was detected in expired air. The peak amount of label was detected in bile < 30 min after injection with either compound and in urine about 25 h later; significant amounts were present in both urine and bile about 8 h later (Fishbein et al., 1969). A series of studies were performed on young male Charles River CD rats with piperonyl butoxide labelled with 14C on the alpha-carbon of the 2-(2-butoxyethoxy)ethoxymethyl side-chain. Four rats were given a single dose of about 500 mg/kg bw (15.6 ± 0.4 µCi) by gavage. An average of 0.18% of the administered radiolabel was expired as carbon dioxide during the 24 h after treatment. Four rats were given a single dose of about 500 mg/kg bw (14.4 ± 0.7 µCi) by gavage; blood samples were then collected from the tail vein for 24 h and analysed for radioactivity. Plasma radioactivity reached a peak 3-12 h after treatment and dropped to about half the peak level within 24 h. Four rats were given a single dose of about 500 mg/kg bw (14.1 ± 1.3 µCi) by gavage; urine and faecal samples were collected and weighed 4, 8, 12, and 24 h after treatment and then every 24 h for seven days. Most of the radiolabel was recovered in urine and faeces 12-2.4 h after treatment; by 168 h after treatment, an average of about 38% of the administered radioactivity was recovered in urine and 62% in faeces. Twenty rats were given a single dose of about 500 mg/kg bw by gavage; groups of five rats were killed 1, 6, 24, 48, and 168 h after treatment, and several tissues were examined for radioactivity. At each interval, the highest levels of radiolabel were found in the gastrointestinal tract and its contents; high levels were also found in lungs, liver, kidneys, fat, prostate, and seminal vescicles. At 1, 6, 24, 48. and 168 h, 62, 67, 37, 13, and 1%, respectively, of the administered radiolabel was recovered. Five rats received piperonyl butoxide at about 500 mg/kg bw per day for 13 days and then a single dose of about 500 mg/kg bw of radiolabelled compound (9.6 ± 0.2 µCi) by gavage. Most of the radiolabel was recovered in urine and faeces 12-48 h after treatment. By 168 h after treatment, an average of about 43% of the radiolabel was recovered in urine and 54% in faeces (Selim, 1985). (b) Effects on enzymes and other biochemical parameters Many studies have been performed in vitro and in vivo to elucidate the mechanism of action of piperonyl butoxide. A single intraperitoneal injection of 450 mg/kg bw inhibited microsomal mixed-function oxidases in the livers of male Swiss-Webster mice; the duration and extent of inhibition depended on the substrate used (Skrinjaric-Spoljar et al., (1971). In male Swiss mice given a single intraperitoneal dose of 160 mg/kg bw of piperonyl butoxide, 50-60% inhibition of dimethyl- aminopyrine and hexobarbital hydroxylases was found 1 h after treatment (Jaffe et al., 1968).A dose-dependent, biphasic effect was observed on the ortho and para hydroxylations of biphenyls by liver microsomes of mice treated with 10-640 mg/kg bw of piperonyl butoxide intraperitoneally, para-Hydroxylation was inhibited by 80% at the highest dose 30 min after treatment but had recovered within 24 h; ortho-hydroxylation was induced by up to 150% 1 h after treatment, and activity was still elevated after 96 h in the groups at the highest dose (Jaffe et al., 1969). Piperonyl butoxide inhibits ethylmorphine N-demethylation by liver microsomes in vitro. The inhibition is proportional to the amount of cytochrome P450-piperonyl butoxide metabolite (unknown) complex formed. Differences between liver microsomes from rats and mice may account for the greater sensitivity of mice to inhibition of drug metabolism by piperonyl butoxide: the Ki for inhibition of ethylmorphine N-demethylase was found to be 19 µmol/litre in rats and 6 µmol/litre in mice (Franklin, 1972). Mouse liver homogenates (20% w/v in 50 mmol/litre phosphate buffer, pH 7.4) were fractioned into nuclear, mitochondrial, microsomal, and soluble fractions, which were incubated with labelled piperonyl butoxide. NAD, NADP, NADH, or NADPH was sometimes added as a cofactor. Only the microsomal fraction had significant metabolic activity in the presence of NADPH and, to a lesser extent, with NADH (Kamienski & Casida, 1970). Male CF-1 mice were given a single intraperitoneal dose of piperonyl butoxide (purity, 87-89%) at 0.5-25 mg/kg bw 1 h before intraperitoneal administration of 40 mg/kg bw pentobarbital or 100 mg/kg bw zoxazolamine. Pentobarbital-induced sleeping time was significantly increased by 10 or 25 mg/kg bw piperonyl butoxide, and zoxazolamine-induced paralysis time was significantly increased by 5, 10, or 25 mg/kg bw (Conney et al., 1972). Skinjaric-Spoljar et al. (1971) found that a single intraperitoneal dose of 22 mg/kg bw piperonyl butoxide to mice increased the hexobarbital (62.5 mg/kg bw intraperitoneally) sleeping time from 28 to 100 min. Male Sprague-Dawley rats were given single intraperitoneal doses of piperonyl butoxide (purity, 87-89%) at 67-1000 mg/kg bw 1 h before intraperitoneal administration of pentobarbital (25 mg/kg bw) or zoxazolamine (70 mg/kg bw). Pentobarbital-induced sleeping time was significantly increased by 1000 mg/kg bw piperonyl butoxide, and zoxazolamine-induced paralysis time was significantly increased by 333 or 1000 mg/kg bw (Conney et al., 1972). Male mice and rats were given single intraperitoneal doses of piperonyl butoxide 1 h before injection of 200 mg/kg bw antipyrine. The NOAELs for effects on antipyrine metabolism were 100 mg/kg bw in rats and 0.5 mg/kg bw in mice (Conney et al., 1972). Groups of six male weanling Sherman rats were fed technical-grade piperonylbutoxide (purity, 80%) at dietary concentrations of 0, 1000, 5000, or 10 000 ppm for one, four, or eight weeks. The activities of hexobarbital oxidase, aniline hydroxylase, para-nitroanisole demethylase, nitroreductase, and glucuronyltransferase and the P450 content were increased two- to fourfold by 5000 or 10 000 ppm piperonyl butoxide. Liver weights and microsomal protein content were increased to a maximum of 50-70%. Electron microscopy showed enlargement and extensive proliferation of the smooth endoplasmic reticulum in liver parenchymal cells. The dose of 1000 ppm had minimal effects on liver weight and on P450 and glucuronyl transferase activity and no effect on proliferation of the smooth endoplasmic reticulum. Maximal effects on P450 content and on the activity of P450-related enzymes were observed after one week of treatment. The maximal effect on glucuronyltransferase activity was observed between four and eight weeks of treatment (Goldstein et al., 1973). Piperonyl butoxide (purity unsepcified) dissolved in corn oil was administered to 10 male Sprague-Dawley rats at 400 mg/kg bw intraperitoneally; another group of animals received 100 mg/kg bw of piperine intraperitoneally. Control animals received 2 ml/kg bw corn oil. Groups of five animals were sacrificed 1 and 24 h after treatment, and hepatic levels of cytochromes P450 and b5, proteins, and the activities of NADPH cytochrome c reductase, benzphetamine N-demethylase, aminopyrine N-demethylase, and aniline hydroxylase were determined. The microsomal protein level was not affected by treatment. Piperonyl butoxide decreased the P450 but not the b5 level by about 30% after 1 h; however, after 24 h the contents were increased by about 100 and 30%, respectively. NADPH cytochrome c reductase activity was increased by 50% 24 h after treatment. The activities of N-demethylases and aniline hydroxylase were decreased by 20 and 50%, respectively, 1 h after administration of either piperine or piperonyl butoxide. By 24 h, the activities were still low in piperine-treated animals but had increased by 30-80% in those given piperonyl butoxide (Dalvi & Dalvi, 1991). Single intraperitoneal doses of 400 mg/kg bw piperonyl butoxide were given to male CD-1 mice 1 h before a single intraperitoneal dose of parathion-methyl, azinphos-methyl, parathion, or azinphos-ethyl, or their oxygen analogues. The LD50 of the oxygen analogues was not altered whereas that of the methyl homologues was reduced, with a 40-fold increase in the LD50 for parathion-methyl and a threefold increase in that for azinphos-methyl; that of the ethyl homologues was increased, with a 50% decrease in the LD50 for parathion and an 85% decrease for azinphos ethyl. The plasma levels of all pesticides were increased by three- to sevenfold in piperonyl butoxide-pretreated animals 30 min after treatment (Levine & Murphy, 1977a). It has been suggested that detoxification of parathion-methyl, but not that of parathion- or azinphos-ethyl, continues through uninhibited glutathione-dependent pathways (Mirer et al., 1977; Levine & Murphy, 1977b). A single intraperitoneal dose of 600 mg/kg bw piperonyl butoxide to three-month-old CD-1 mice reduced the hepatotoxicity (as assessed by reduced glutathione content, plasma sorbitol dehydrogenase, and histopathological liver necrosis) caused by an oral dose of 600 mg/kg bw acetominophen given 2 h earlier or 1 h later. Since the hepatic mixed-function oxidase system generates a toxic, electrophilic metabolite of acetominophen, piperonyl butoxide probably acts by inhibiting: that enzymatic system (Brady et al., 1988). Pretreatment of groups of 10 male Syrian golden hamsters with 400 mg/kg bw piperonyl butoxide given subcutaneously 2 h before subcutaneous injection of 17.8 mg/kg bw N-nitrosodiethylamine twice weekly for 20 weeks inhibited the development of pulmonary carcinogenesis by the nitrosamine. The numbers of animals with lung tumors were 0 controls, 6 treated only with N-nitrosodiethylamine, 0 treated with piperonyl butoxide and nitrosamine, and 0 given only piperonyl butoxide. Tracheal tumors were found in 0, 10, 5, and 0 animals in the four groups, respectively. The protective effect was associated with reduced (by 50% or more) covalent binding of N-[ethyl-1-14C]-nitroso-diethylamine to macromolecules in trachea, lung, and liver (Schuller & McMahon, 1985). Eight-week-old male CD-1 mice were fed diets containing piperonyl butoxide at concentrations adjusted to provide doses of 0, 10, 30, 100, or 300 mg/kg bw per day or sodium phenobarbital at 0.05% (w/w) for 42 days. Replicative DNA synthesis was studied by implanting seven-day osmotic pumps to administer 5-bromo-2'-deoxyuridine (BrDU) during days 0-7 and 35-42 of treatment; liver sections were immunostained with an antibody to BrDU, and the percentage of hepatocyte nuclei undergoing replicative DNA synthesis was calculated by microscopic examination of at least 1000 nuclei. Xenobiotic metabolism was assessed by measuring the liver P450 content and the activities of 7-ethoxyresorufin O-deethylase, 7-pentoxyresorufin O-depentylase, and ethylmorphine N-demethylase in liver microsomes. Sodium phenobarbital was used as a positive control. The relative liver weight was increased by about 15% after seven days of treatment with 300 mg/kg bw per day of piperonyl butoxide and by about 20% with sodium phenobarbital; after 42 days, it was increased by about 10% after treatment with 100 and by about 20% after treatment with 300 mg/kg bw piperonyl butoxide. Midzonal liver-cell hypertrophy was observed in mice given 300 mg/kg bw per day for seven or 42 days or 100 mg/kg bw per day for 42 days. Sodium phenobarbital induced centrilobular hypertrophy after either seven or 42 days of treatment. Replicative DNA synthesis was induced to 350% by the high dose of piperonyl butoxide and to 825% by sodium phenobarbital for seven days; no significant increase was observed after 42 days at any dose. A dose-related increase in microsomal protein and P450 content was observed on day 42, and the increases were statistically significant at doses > 100 mg/kg bw. Inconsistent increases were observed in the activities of 7-ethoxyresorufin O-deethylase and 7-pento- xyresorufin O-depentylase in piperonyl butoxide-treated mice, but a dose-related increase from 20 to 50% in the activity of ethylmorphine N-demethylase was seen on day 42. Treatment with sodium pheno- barbital for 42 days resulted in increases in all of the measured parameters. Piperonyl butoxide (and sodium phenobarbital) thus caused a transient stimulation of liver-cell replication and a permanent effect on liver weight, morphology, and enzyme induction at doses that induced liver nodules in long-term studies (Phillips el al., 1995). 2. Toxicological studies (a) Acute toxicity Groups of five Sprague-Dawley CD rats of each sex were exposed by inhalation for 4 h to a mean analytical concentration of 5.9 mg/litre piperonyl butoxide (purity, 90.78%). The particle median aerodynamic diameter was 2.6 µm; about 15% of the aerosol was < 1 µm in diameter and about 95% < 10 µm. All animals survived the exposure and the 15-day observation period after treatment. Exposure caused excessive lacrimation and salivation, nasal discharge and laboured breathing. All animals recovered. No remarkable signs were seen post mortem (Hoffman, 1991). Other data are reported in Table 1. (b) Short-term toxicity Mice Groups of 10 male and 10 female ICR (Crj:CD-1) mice were fed diets containing 0, 1000, 3000, or 9000 ppm piperonyl butoxide (purity unspecified) for 20 days. Animals were observed daily for mortality; body weight was measured and clinical observations were made on days 1, 2, 3, 7, 14, and 20; the food consumption of five animals per cage was measured on days 0-3, 3-7, 7-14, and 14-20. At the end of treatment, blood clinical chemistry was assessed, liver, kidneys, and spleen were weighed, and livers and kidneys were examined histologically. No deaths occurred. The body weights of animals at the high dose were about 15% lower than those of controls at the end of the study, and those of females at the middle dose were about 10% lower on day 2 and about 8% lower at termination (not statistically significant). The lowered body weights were apparently associated with decreased food intake. The weights of livers showed a dose-related increase in both males (by 22% at the low dose, 63% at the middle dose, and 79% at the high dose) and females (62% at the middle dose and 78% at the high dose); at the high dose, the weights of the kidneys were reduced by 29% in males and 18% in females, and the weights of the spleen by 25% in males and 33%, in females. In animals at the high dose, a 31% increase in serum cholesterol was seen in males and a 67% increase in females, a 28% increase in serum phospholipids was seen in males and a 38% increase in females, a 19% Table 1. Acute toxicity of piperonyl butoxide in animals Species Sex Route LD50 or LC50 Purity Reference (mg/kg bw or (%) mg/litre air) Mouse NR Oral 4.0 NR Negherbon (1959) Rat Male Oral 4.57 90.78 Gabriel (1991a) Female 7.22 NR Oral 8.0-10.6 NR Sarles et al. (1949) NR Oral 13.5 NR Lehman (1948) NR Oral 11.5 NR Lehman (1951) Male, female Inhalation (4 h) > 5900 90.78 Hoffman (1991) NR Subcutaneous > 15.9 NR Sarles et al. (1949) Rabbit Male, female Dermal > 2 90.78 Gabriel (1991b) NR Oral 2.7-5.3 NR Sarles et al. (1949) Cat NR Oral > 10.6 NR Sarles et al. (1949) Dog NR Oral > 8.0 NR Sarles et al. (1949) NR, Not reported increase in total serum proteins occurred in males and an 18% increase in females, and a 235% increase in gamma-glutamyl transpeptidase was seen in females. Some of these levels were also increased in the animals at the middle dose. Microscopic examination of the liver showed hypertrophic hepatocytes, single-cell necrosis, and cell infiltration in the centrilobular area in all mice at the high dose. The kidneys were unremarkable. The NOAEL for effects on the liver was 1000 ppm, equivalent to 150 mg/kg bw per day (Fujitani et al., 1993a). Groups of 20 Crj:CD-1 male mice were fed diets containing 0, 1500, 3000, or 6000 ppm piperonyl butoxide (purity unspecified) for seven weeks. Food intake was measured every week and behavioural tests were performed at weeks 4 (exploratory behaviour), 6 (multiple water T-maze), and 7 (exploratory behaviour) of treatment. A treatment- related reduction in food intake was observed in animals at the middle and high doses during the first week of treatment. No consistent, significant effect was observed in the T-maze test or in the exploratory behaviour test at week 4. At week 7, some parameters in the exploratory behaviour test were altered (Tanaka, 1993). Rats Hypertrophy of periportal cells with slight fatty changes were observed in rats fed a diet containing 5000 ppm piperonyl butoxide for 17 weeks (Lehman, 1952a,b). Feeding of six weekly doses of up to 224 mg/kg bw of active ingredient to rats caused no observable effects at autopsy three weeks after the final dose, but few details were given (Sarles et al., 1949). In a range-finding study, groups of 10 male and 10 female Sprague-Dawley rats were fed diets containing concentrations of piperonyl butoxide adjusted to obtain doses of 0, 62.5, 125, 250, 500, 1000, or 2000 mg/kg bw per day for four weeks. All animals were observed for mortality and morbidity twice daily, and body weight and food consumption were measured weekly. Haematological and biochemical tests were performed on day 24 or 25 of treatment. At termination, survivors were necropsied, certain organs were weighed and microscopic examinations were performed on several organs. Six animals died before termination, but the deaths were considered to be due to anaesthesia for bleeding. General signs of toxicity, such as prominent backbone, thinness, poor fur condition, brown staining and piloerection, were observed in animals at the highest dose. Body-weight gain was reduced by about 20% in females at 500 mg/kg bw per day, by 27% in males and 37% in females at 1000 mg/kg bw per day, and by 66% in males and 92% in females at 2000 mg/kg bw per day. These reductions were only partially associated with reduced food intake. Haematology and clinical biochemistry showed no significant alterations. Absolute and relative liver weights were increased in animals given doses > 500 mg/kg bw per day; the relative liver weights were also increased in males at 250 mg/kg bw per day. The relative weights of the adrenals, kidneys, and brain were slightly increased in the group at the highest dose and in some animals at 1000 mg/kg bw per day. Eosinophilia and loss of vacuolation in hepatocytes were noted in all treated animals, and the severity of these lesions was dose-related. These may be adaptive changes. Necrosis of hepatocytes and cytoplasmic inclusions were observed in animals at 1000 and 2000 mg/kg bw per day. The NOAEL was 125 mg/kg bw per day on the basis of effects on the liver (Modeweg-Hansen et al., 1984). In a study preliminary to the study of carcinogenicity by the same authors summarized below, groups of 10 Fischer 344/DuCrj rats of each sex were fed diets containing 0, 2500, 5000, 10 000, 20 000, or 30 000 ppm piperonyl butoxide (purity, 89%) for 13 weeks. At termination, survivors were necropsied, and limited microscopic examination was performed. One male at the high dose died before termination. The final body weights and body-weight gains were reduced in a dose-related manner in all treated males; in females, a significant effect was seen only at the two highest doses. Liver weights were increased in all treated animals, by up to 50% in males and 108% in females. Absolute kidney weights were increased in animals at the high dose, and the relative weight was also increased in groups at lower doses. Hepatocyte hypertrophy and focal necrosis were seen in animals at higher doses (data not shown). No relevant macro- or microscopic lesions were observed in the digestive tract, but the caecum was not examined histologically. There was no NOAEL because of effects on the liver at all doses (Maekawa et al., 1985). Groups of 15 Charles River CD rats of each sex were exposed by inhalation for 6 h per day, five days per week, for 13 weeks to piperonyl butoxide (purity, 90.78%) at mean analytical concentrations of 15, 74, 155, or 512 mg/m3. The highest concentration was the maximum that could be generated at the appropriate particle size. Fifteen controls were exposed to conditioned room air only. The concentrations in chamber air were monitored gravimetrically four times per day and by gas chromatography once a day. Particle size distribution was measured once during each exposure. The test aerosol had a mass median aerodynamic diameter of 1.7 µm with a geometric standard deviation of 2.6. On average, 37% of the particles were < 10 µm in diameter and 29% < 1 µm. Abnormal signs were looked for once during each exposure, and detailed physical examinations were conducted on all animals once before treatment and weekly during treatment. Ophthalmoscopic examinations were performed on all animals before treatment and on the day before sacrifice. Body weight was recorded before exposure, immediately before exposure on test day 1, weekly thereafter, and just before sacrifice. At termination, haematological and blood chemical parameters were evaluated in all animals, selected organs were weighed, complete gross post-mortem examinations were conducted, and selected tissues from all animals were examined microscopically. Body-weight gain and food consumption were not affected by exposure, and all animals survived to the end of treatment. Ophthalmoscopic examinations showed no indication of exposure-related ocular effects. There was a dose-related increase in nasal discharge, dried material on the facial area and extremities, and anogenital staining in animals at 155 and 512 mg/m3. The serum levels of aspartate and alanine aminotransferases and of glucose were slightly decreased (10-28%), while blood urea nitrogen, total protein, and albumin levels were slightly increased (4-10%) in animals of each sex at the high dose. Not all of these differences were statistically significant, and a dose-response relationship was not seen consistently; however, a similar trend was seen in animals of each sex. Statistically significant increases in the absolute and relative weights of the livers and kidneys were seen in animals at the high dose; the relative kidney weights were increased by 10-12%, and the absolute and relative liver weights were both increased by 20-29%. Relative liver weights were also significantly elevated (8-9%) in males and females at 155 mg/m3. Vesiculation and vacuolation of the hepatocellular cytoplasm was seen in almost all treated animals but tended to be more pronounced in those at the highest level. No clear dose-related increase in either incidence or severity was observed. Squamous or squamoid metaplasia of the pseudostratified columnar epithelium of the larynx was seen in several exposed animals and one control female, the severity being greater in animals at the high dose. Similar metaplastic changes were seen in the columnar epithelium lining the ventral diverticulum in several animals at 512 mg/m3 and in one female at 15 mg/m3. Hyperplasia and hyperkeratosis of the squamous epithelium normally found in the larynx were seen in a small number of animals at 512 mg/m3. Laryngeal mucosal inflammation was seen in all treated animals and was slightly more severe in animals at the highest dose. All of the changes were considered to be localized responses indicative of irritation rather then systemic toxicity. Other findings in tissues and organs examined macroscopically and microscopically post mortem were unremarkable. No systemic toxicity was seen at 155 mg/m3; effects on the liver and kidney were seen at 512 mg/m3 (Newton, 1992). Groups of 10 male and 10 female Fischer 344/DuCrj rats were fed diets containing 0, 6000, 12 000, or 24 000 ppm piperonyl butoxide (technical grade of unspecified purity) for 13 weeks. Animals were observed daily for mortality; body weight and clinical signs were monitored daily for the first five days and then twice weekly. Food and water consumption was measured on days 4, 11, 18, and 39 for about six rats in each group. At the end of treatment, haematological and blood chemical parameters were determined, animals were necropsied, and selected organs were weighed; the liver and kidneys were examined histologically. There were no deaths. Clinical signs consisted of nose bleeds from about day 2 to day 20 and dose-dependent abdominal distension. In animals at the high dose, food consumption was reduced by about 46% and water consumption by 28% on day 4 but not at other times. The body weights of animals at the high dose were significantly reduced, by 36% in males and 24% in females. Blood haemoglobin levels were decreased in a dose-dependent manner, but the decrease was statistically significant only in animals at the high dose (by 10-11%) and females at the middle dose (by 7%). A reduced mean corpuscular haemoglobin content was also observed in females at the high dose. Serum albumin was increased by 16-23%, cholesterol by 88-93%, gamma-glutamyl transpetidase activity to five to six times the control values in males at the high dose, and urea nitrogen by 24% in males at that dose. Serum protein was increased in all treated females and serum phospholipid in females at the high dose; decreases were seen in serum levels of triglyceride in all males and bilirubin and glucose in males at the high dose. Absolute and relative liver weights were increased in a dose-related manner, but were significantly increased only in males at the middle dose (by 47%) and males and females at the high dose (by 57-94%). Relative kidney weights were increased in a dose-related manner to up to 1.42% of control values. Hypertrophic hepatocytes containing a basophilic, fine granular substance were seen in animals at the high dose. In the periportal area, marked vacuolation of hepatocytes was observed, with occasional coagulative necrosis and oval-cell proliferation. In male rats, atrophy of the epithelium of the proximal convoluted tubules was observed in the renal cortex. There was no NOAEL because of effects on the liver and kidney (Fujitani et al., 1992). In a subsequent study performed under the same experimental conditions, haematological, clinical chemical, and morphological observations after 1, 2, 4, or 12 weeks of treatment showed that all of the alterations occurred in a time-dependent manner, and that some of them (increased liver and kidney weights, morphological alterations in the liver) were already present after one week (Fujitani et al., 1993b). Rabbits Three weekly doses of up to 108 mg/kg bw active ingredient of a 5% emulsion of piperonyl butoxide showed no effects at autopsy three weeks after the final dose, but few details were given (Sarles et al., 1949). Dogs Groups of one to three dogs of each sex were given piperonyl butoxide at 0, 3, 32, 106, or 320 mg/kg per day orally in capsules on six days per week for one year. All dogs at the two highest doses lost weight, but large variations in body-weight gain and the small number of animals prevented meaningful comparisons between the controls and animals at the lower doses. A dose-related increase in relative liver weight (no statistical analysis reported) was observed, which was associated with unspecified histopathological changes. Increased kidney and adrenal weights were observed at 100 and 320 mg/kg bw per day (Sarles & Vandergrift, 1952). Groups of two beagle dogs of each sex were fed diets containing piperonyl butoxide (purity, 90.78%) for eight weeks at concentrations corresponding to 500, 1000, 2000, or 3000 ppm active ingredient. The diets were prepared weekly; the actual concentrations and the homogeneity of the mixture were measured at three intervals and found to be satisfactory. Animals were observed at least twice daily for mortality and signs of toxicity; detailed observations were recorded at least once weekly, and body weight and food consumption were recorded weekly. Physical examinations and haematological and biochemical tests were conducted on all animals before exposure and at termination. All major tissues and organs were examined microscopically post mortem. Selected organs were weighed. All animals survived to study termination. Reduced body-weight gains were seen in males and females receiving 1000 ppm (14 and 9% of the initial body weight, respectively), 2000 ppm (6 and 7%), and 3000 ppm (7 and 4%) ppm in comparison with the control group (17% and 14% increases). Decreased food consumption (by 19 and 23%) was observed animals at 3000 ppm. There were no treatment-related changes in haematological parameters. Males and females at 2000 and 3000 ppm had alkaline phosphatase activities that were about 1.5 times the control value and increased absolute and relative liver and gall-bladder weights. No macroscopic changes were observed that could be attributed to treatment, and treatment-related microscopic changes were limited to diffuse, mild hypertrophy of hepatocytes in all treated males and in females at the two highest doses. There was no NOAEL because of effects on the liver (Goldenthal, 1993a). Groups of four beagle dogs of each sex were fed diets containing piperonyl butoxide (purity, 90.78%) for one year at concentrations corresponding to 100, 600, and 2000 ppm active ingredient. The diets were prepared weekly and stored at room temperature. The stability of the compound was assessed twice: an initial test showed a loss of about 10% over 10 days, possibly due to technical problems; a second test showed 97-101% of the initial concentration on day 10. The actual concentrations were measured 16 times and were found to be 87-110% of the nominal concentrations. The homogeneity of the mixture was also found to be satisfactory. The dogs were observed at least twice daily for mortality and signs of toxicity; detailed observations were recorded weekly. Body weight and food consumption were recorded weekly for the first 14 weeks and every two weeks thereafter. Ophthalmoscopic examinations were conducted before the beginning of treatment and at termination. Physical examinations were conducted on all animals before exposure and after 3, 6, 9, and 12 months of treatment. Haematological and biochemical tests and urinalyses were conducted on all animals after 6 and 12 months. All animals were examined post mortem, and all major tissues and organs were examined microscopically. Selected organs were weighed. All animals survived to the end of the study, with no relevant clinical or ophthalmological signs. The body weights of males and females receiving 2000 ppm piperonyl butoxide were 2% lower to 3% higher than the initial weights, whereas those of controls were 22-25% higher. Treatment- related decreases in food consumption were observed in males at 600 (by 15%) and 2000 (by 20%) ppm. Small, not statistically significant, not dose-related decreases in food consumption were observed in treated females. No treatment-related change in haematological parameters was observed. The activity of alkaline phosphatase was increased to three to five times the control values in animals at 2000 ppm after 6 and 12 months, and cholesterol levels were decreased (not statistically significant) at these intervals in females. Males and females at this dose had increased absolute (by 22 and 36%) and relative (by 52 and 86%) liver and gall-bladder weights, and small increases in thyroid and parathyroid weights (average, 34%) were observed in females. These changes were not associated with microscopic changes in the thyroid and were considered to be of questionable biological significance. No macroscopic pathological changes were observed that could be attributed to treatment. Treatment-related histopathological changes were limited to diffuse, mild hypertrophy of the hepatocytes in males and females at 2000 ppm. The NOAEL was 100 ppm, equal to 16 mg/kg bw per day, on the basis of effects on the liver, some clinical chemical alterations, and reduced body-weight gain at 2000 ppm (Goldenthal, 1993b). Monkeys Two African green monkeys were given 32 or 106 mg/kg bw per day piperonyl butoxide orally for six days per week for four weeks. Minimal microscopic changes were observed in the livers (Sarles & Vandergrift, 1952). (c) Long-term toxicity and carcinogenicity Mice Groups of 18 (C57Bl/6 × C3H/Anf)F1 and (C57Bl/6 × AKR)F1 mice of each sex received piperonyl butoxide (purity unspecified) at 100 mg/kg bw or 'Butacide' at 464 mg/kg bw in 0..5% gelatin at seven days of age by stomach tube and the same amount (not adjusted for increasing body weight) daily up to four weeks of age; subsequently, the mice were fed diets containing 300 ppm. The dose was reported to be the maximal tolerated dose for infant and young mice. All animals were killed when they were about 70 weeks of age, and their tumour incidences were compared with those of 79-90 necropsied mice of each sex and strain, which had either been untreated or had received gelatine only. No significant difference in the incidence of tumours was found between treated and control mice, although the authors concluded that additional evaluation was required (Innes et al., 1969). This study was not considered to be adequate by the Meeting. Groups of 50 B6C3F1 mice of each sex were fed diets containing 5000 or 10 000 ppm piperonyl butoxide (purity, 88.4%) for 30 weeks; the doses were decreased to 500 or 2000 ppm for the following 82 weeks, due apparently to a greater than expected decrease in body-weight gain. The control group consisted of 20 males and 20 females. Animals were observed twice daily for signs of toxicity; body weight was recorded at least once per month. Necroscopic examination was performed at termination on all moribund animals and on those found dead, unless precluded by autolysis. Major tissues and organs and all gross lesions were examined microscopically. At termination, 85% of control males and 75% of control females, 82% and 68% at the low dose, and 84% and 70% at the high dose, respectively, were still alive. Body weight was reduced in a dose-related manner, by up to about 15% in females at the high dose at termination. No treatment-related increase in tumour incidence was found, but hepatocellular carcinomas occurred frequently, especially in males, with incidences of 50% in controls, 34%, at the low dose, and 40% at the high dose. No statistically significant differences were found in the incidences of neoplastic and non-neoplastic lesions (US National Cancer Institute, 1979) Groups of 60 CD-1 mice of each sex were fed diets containing piperonyl butoxide (purity, 90.78%) at concentrations adjusted to give doses of 0 (two control groups), 30,100, or 300 mg/kg bw per day, for 78 weeks. The diets were prepared weekly and the concentrations adjusted on the basis of body weights and food consumption. The diets were analysed for the actual concentration, homogeneity, and stability of piperonyl butoxide. The average actual concentrations at the low and high doses were 99 and 95%. The homogeneity and stability (no decrease in concentration after 14-21 days) of piperonyl butoxide in the diet were considered to be satisfactory. Animals were observed twice daily for signs of toxicity. Food consumption and body weight were determined weekly for the first week and then every other week. Haematological measurements were made for 10 rats of each sex in the control and high-dose groups at week 52 and for all groups at termination. All surviving animals were necropsied; major tissues and organs from controls and animals at the high dose and the lungs, liver, kidneys, and gross lesions from other groups were examined microscopically. All slides from the livers underwent an independent pathological review; the results reported here are the consensus or majority opinions of all the pathologists involved. No treatment-related clinical signs or palpable masses were observed. The mortality rates were (males/females) 27/32, 32/27, 27/38, 22/33, and 40/18% in the first control group, animals at 30, 100, and 300 mg/kg bw per day, and the second control groups, respectively. Body weights and body-weight gains of animals at the high dose were slightly (occasionally statistically significantly) decreased. No significant effects on food consumption were observed. Haematological parameters were also unaffected by treatment. A dose-related increase in absolute and relative liver weights was observed in mice of each sex at the middle and high doses. Hepatocellular hypertrophy was more frequent in males at the high (72%) and middle doses (27%) than in controls (10 and 18%) and in females at the high dose (15%; 0 and 7% in controls). Hepatocellular hyperplasia (also called eosinophilic/clear-cell focus), characterized by aggregates of hepatocytes with a swollen eosinophilic cytoplasm, was present in 8% of males at the high dose, 2% of females at the middle dose, and 7% at the high dose. The incidences of hepatocellular hyperplasia were 0 and 3% in control males and 0% in both female control groups. The incidence of hepatocellular adenomas was higher in male mice at the middle (37%) and high (47%) doses than in either control group (15 and 13%) and in females at the high dose (17%; 3% in controls). The hepatocellular adenomas observed in many treated animals were composed of large, polyhedral, densely-packed cells with abundant granular eosinophilic cytoplasm. This appearance is different from that of spontaneous adenomas found in CD-1 mice, where small to medium, well-differentiated, basophilic cells, distributed in solid to normal sinusoidal patterns, are found. Only the incidence of the former type of adenoma was increased in piperonyl butoxide-treated mice. A nonsignificantly increased incidence of hepatocellular carcinomas was observed in males at the high dose (12%; 3% in controls). No other treatment-related neoplastic or non-neoplastic lesion was found. The NOAEL was 30 mg/kg bw per day on the basis of effects on the liver (Hermanski & Wagner, 1993). A 12-month study of carcinogenicity was conducted in male Crj:CD-1 mice fed diets containing 0 ( n = 52), 6000 ( n = 53), or 12 000 ( n = 100) ppm piperonyl butoxide (purity, 94.3%; no detectable safrole or isosafrole). Animals were observed daily for mortality and morbidity; those that died or were sacrificed at termination were necropsied, and gross lesions and the liver were examined histologically. The mortality rates were 6% of controls, 2% at the low dose, and 19% at the high dose. Terminal body weight was found to have been reduced by 17% at the low dose and 29% at the high dose. Hepatocellular hyperplasia was seen in 38% of animals at the low dose and 8% at the high dose, hepatocellular adenomas in 13 and 22%, hepatocellular carcinomas in 11 and 52%, and haemangioendothelial sarcoma in 2 and 42%. It should be noted that the hepatocellular adenomas and carcinomas may have obscured the true dose-response relationship for hepatocellular hyperplasia. A condition termed 'post-necrotic peliosis', consisting of multifocal necrosis with blood cysts, was also found in 17% of animals at the high dose. One control animal showed hepatocellular hyperplasia and one had a hepatocellular adenoma (Takahashi et al., 1994a). Rats Groups of 12 Wistar rats of each sex were fed diets containing 0, 100, 1000, 10 000, or 25 000 ppm piperonyl butoxide for two years, and an additional group was fed a diet containing 1000 ppm piperonyl butoxide plus 167 ppm pyrethrins. Animals were observed daily for clinical signs of toxicity, and food consumption and body weight were determined weekly. Autopsies were performed on all animals. Males and females were paired for the duration of the study, except during nursing (see section ( d)). Body-weight gain was reduced in animals at 10 000 (by 10-20%) and 25 000 ppm (by about 90%), in association with reduced food intake. All animals at the high dose were dead by week 68; the mortality rates in the other groups were (males/females): 30/20%, 40/30%, 40/50%, and 60/60% for controls and animals at 100, 1000, and 10 000 ppm, respectively. The relative weights of livers and kidneys were higher than those of controls in animals at 10 000 (by 40% for liver and kidney) and 25 000 ppm (by 275% for liver and 150% for kidney). These effects were not associated with morphological alterations. The incidence of tumours was not increased (Sarles & Vandergrift, 1952). Sixty Sprague-Dawley Crl:CDR (SD)BR rats of each sex were fed diets containing piperonyl butoxide (purity, 89%) at concentrations adjusted weekly (every two weeks after week 15) to achieve daily intakes of 0 (two groups of controls), 30, 100, or 500 mg/kg bw per day for 104-105 weeks. The stability and homogeneity of the diets and the correspondence of actual to nominal concentrations were checked before and throughout the study and found to be acceptable. The animals were observed for mortality, clinical signs, food consumption, body weight, and ophthalmoscopic, haematological, clinical biochemical, urinary, and pathological parameters. Complete histological examinations were made of animals in the two control groups and at the high dose and of those animals at the low and intermediate doses which died during the study. Histological examination of animals at these doses killed at the end of the study was limited to the liver, kidney, lung, thyroid, testis, epididymides, ovary, and any observed abnormalities. No clinical signs related to treatment were observed. Sialodacryoadenitis was diagnosed in a large percentage of treated animals in weeks 25-28 and weeks 63-67. Body weights were lower in rats of each sex at 500 mg/kg bw per day than in controls throughout the study. At week 104, the mean body weight was 20-30% lower than the control value. A trivial reduction in food consumption was observed in animals of each sex at the highest dose. Ophthalmoscopic examination in week 99 revealed no changes attributable to treatment, and haematological tests and urinalysis revealed no adverse effects. Female rats receiving 500 mg/kg bw per day had higher cholesterol levels than controls throughout the study and increased blood urea nitrogen at 98 weeks. Other statistically significant differences in biochemical parameters were of no biological relevance. At the end of the study, the mortality rates were 82, 78, 87, 82, and 78% in males and 55, 68, 63, 43, and 50% in females at 0 (two groups), 30, 100, and 500 mg/kg bw per day, respectively. Increased liver weights were seen in animals of each sex at 100 and 500 mg/kg bw per day, corresponding to a higher incidence of macroscopic enlargement associated with hyperplasia and hypertrophy of centrilobular hepatocytes and enlarged eosinophilic cells, which occasionally contained a brownish cytoplasmic pigment. Increased kidney weights were observed in female rats at the two highest doses, corresponding histologically to a higher incidence of chronic interstitial glomerulonephritis. Other histological changes were confined to the endocrine organs: Enlarged thyroid glands were observed in animals of each sex at 500 mg/kg per day, corresponding histologically to a higher incidence of generalized and focal hyperplasia of follicles and increased pigment deposition in the colloid. A slightly higher incidence of adrenal and ovarian enlargement seen among females receiving 500 mg/kg per day was not associated with histological changes. In males, there was a negative trend in the presence of enlarged, focal, coarsely vacuolated cortical cells in the adrenals. The combined incidence of bilateral and unilateral testicular atrophy was comparable between groups, but there were significant differences from controls in the incidences of bilateral testicular atrophy at all doses, with 17, 33, 47, and 43% at 0, 30, 100, and 500 mg/kg bw per day, respectively. After an additional, full review of the relevant data, this finding was considered unlikely to be related to treatment because the atrophy was not associated with degeneration of seminiferous tubules or aspermatogenesis, and testicular weights were not decreased. Morphometric analysis of the pituitary gland area showed reduced size in males at the highest dose. A trend analysis of tumour incidence with dose showed both increases (in the lymphoid system and thyroid) and decreases (in mammary glands and pituitary). These differences were not statistically significant in pairwise comparisons between groups, and the incidences were within the range of those of historical controls of this strain of rats. These observations provide no evidence that the treatment had carcinogenic potential, but the wide range of gross alterations, effects on organ weight, and histological changes observed reflect the biological activity of the test compound. The enlargement of the liver, the primary target organ, is consistent with the activity of the compound as a hepatic enzyme inducer. The wide differences in the incidences of morphological changes and lesions in endocrine and hormone-sensitive organs between controls and treated groups strongly support the interpretation that they are the results of changes in hormonal levels brought about by hepatic enzyme induction. The NOAEL was 30 mg/kg bw per day on the basis of effects on the liver (Graham, 1987). Groups of 50 Fischer 344/Du Crj rats of each sex were fed diets containing 0, 5000, or 10 000 ppm piperonyl butoxide (purity, about 89%) for two years at doses selected on the basis of the results of the 13-week study by the same authors, summarized above. Animals were observed daily for clinical signs and mortality; food consumption was measured monthly, but the frequency of body-weight measurement was not stated. Treatment was stopped after 104 weeks, and surviving animals were sacrificed after six more weeks on the basal diet. All animals, including those sacrificed when moribund or found dead, were necropsied and a complete histological examination was performed. The mortality rates were (males/females) 16/14, 38/22, and 42/34% in controls and animals at 5000 and 10 000 ppm; the increased mortality was statistically significant for animals at the high dose. Just before death, many animals showed signs of anaemia (not specified) and had blood in their faeces. A dose-related reduction in body weight was seen in animals of each sex (statistical analysis not reported), with no concomitant decrease in food intake. No statistically significant difference in the incidence of malignant or benign neoplasms was found, except a decreased incidence of thyroid C-cell adenomas in males at the high dose (9%; 44% in controls). Dose-related increases were seen in the incidences of ulcers (0/0%, 35/2%, and 52/45% in male and female controls and those at the low and high doses, respectively), regenerative hyperplasia (0/0%, 13/0%, and 22/4%), ossification in the ileocaecal mucosa (0/0%, 15/0%, and 20/0%), and haemorrhage of the caecum and colon (0/0%, 10/0%, and 17/12%). The main histological lesions were chronic ulcers with inflammatory-cell infiltration and granulation, sometimes with ossification of the surrounding mucosa. Most of deaths in treated animals before the end of the study were attributed by the authors to lesions leading to anaemia. Piperonyl butoxide was not found to be carcinogenic (Maekawa et al., 1985). Groups of 50 Fischer 344 rats of each sex were fed diets containing 5000 or 10 000 ppm piperonyl butoxide (purity, 88.4%) for 24 months; the control group consisted of 20 animals. The diets were prepared freshly each week and stored at 7°C. Animals were observed twice daily for mortality and underwent a complete clinical examination monthly. The food consumption of 10 animals in each group was measured during the first week of each month; body weights were measured about twice monthly. Moribund animals were sacrificed and necropsied and their organs were examined histologically. All surviving animals were sacrificed and submitted to a complete histopathological examination. All control females and about 80% of treated females survived until termination, whereas no difference in survival was found for males (70-75% survival in all groups). A dose-related reduction in body weight was found for both females (16% at the low dose and 24% at the high dose) and males (7% at the low and 16% at the high dose). No difference was found in the incidence of malignant or benign neoplasms, except for that of lymphoreticular malignant lymphoma which was significantly increased in treated females (14% at the low and 30% at the high dose; 5% in controls) and nonsignificantly decreased in males (30% at the low and 26% at the high dose; 35% in controls). The author concluded that the results were equivocal because of the variability in the historical control data and the difficult diagnosis of these neoplasms (Cardy et al., 1979; US National Cancer Institute, 1979). Groups of 30-33 Fischer 344/DuCrj rats of each sex were fed diets containing 0, 6000, 12 000, or 24 000 ppm piperonyl butoxide (two lots: purity, 94.5 and 94.3%; no detectable safrole or isosafrole) for 95 (males) or 96 (females) weeks. The study was ended before 104 weeks because of the high mortality of males at 12 000 ppm (see below). Animals were observed daily for clinical signs and mortality; body weights were measured monthly. Food consumption was determined in a preliminary experiment involving six rats of each sex per group (duration not reported), which resulted in calculated compound intakes of 537, 1061, and 2002 mg/kg per day by females and 547, 1052, and 1877 mg/kg per day by males at 6000, 12 000 and 24 000 ppm, respectively. Rats that died were necropsied and observed for tumors and non-neoplastic lesions, which were then examined microscopically. At termination, surviving rats were necropsied; hepatic nodules (when multiple nodules were present, three major ones were taken) and major organs were weighed and examined histologically. Blood was collected for haematological tests (including prothrombin and partial thromboplastic times) and for standard clinical chemistry. The mortality rates were 17, 23, 50, and 24% in males and 20, 10, 17, and 21% in females at 0, 6000, 12 000, and 24 000 ppm, respectively. Males at 12 000 ppm began to die as early as week 40 and at a statistically significantly different rate from other groups from week 45. Deaths were most frequently associated with haemorrhage in the caecum. Body weights were reduced in a dose-related manner in all treated animals but statistically significantly only in animals at the middle and high doses. Males and females at the high dose lost weight from week 60, and at termination their body weights were about 50% of those of controls. The weights of all organs except the liver were reduced in animals at the high dose. The absolute liver weights were increased in animals at 12 000 ppm (in males by 22% and in females by 51%) and in females at 6000 ppm (by 29%). During the first month of treatment, rough hair, lethargy, epistaxis, and a fall in food consumption (data not reported) were observed in animals of each sex at 24 000 ppm. Haematological tests showed a significant increase in hypochromic, microcytic anaemia, the severity of which was dose-related, in all treated animals. The most significant findings in plasma were decreased cholinesterase activity and triglyceride contents in animals at all doses and an increased urea nitrogen level in animals at the high dose and in all treated females. Hepatic tumours were observed from week 74 of treatment. Nodular lesions of the liver were observed only in treated animals, and their incidence, numbers per rat, and size were dose-related. Hepatocellular adenomas and carcinomas were found in animals at the middle and high doses: the incidences of adenomas were 27% in males and 13% in females at 12 000 ppm and 15% in males and 30% in females at 24 000 ppm; the incidences of carcinoma were 13% in males and 0% in females at 12 000 ppm and 73% in males and 46% in females at 24 000 ppm. The nodules in animals at the low dose were classified as foci or hepatocellular focal hyperplasia. The only other difference between groups was found for interstitial-cell tumours of the testis, with incidences of 23/25 in controls, 19/23 at 6000 ppm, 13/15 at 12 000 ppm, and 15/25 at 24 000 ppm. Essential (haemorrhagic) thrombocytaemia (defined as > 3 × 106 platelets per microlitre, with a bimodal platelet distribution curve) was found in 0/24 male controls and in 6/23 males at 6000 ppm, 3/15 at 12 000 ppm, and 9/24 at 24 000 ppm and in only 1/25 females at the high dose. Of the non-neoplastic lesions, the following are significant: an increased incidence of stomach haemorrhage (males: 9/33; 5/30 in controls; females: 19/33; 2/30 in controls) at the high dose, an increased incidence of haemorrhage and/or oedema of the caecum in all treated males and in females at the middle dose, an increased incidence of black kidneys in males at the middle and high doses and all treated females, and an increased incidence of whitish spotting in the lungs of males at the middle and high doses. Tubular dilatation, distension of Bowman's space and interstitial fibrosis were found in the kidneys of animals at the high dose (actual numbers not reported) (Takahashi et al., 1994b). (d) Reproductive toxicity Mice In a two-generation study, with one litter per generation, groups of 10 male and 10 female Crj:CD-1 mice were fed diets containing 0, 1000, 2000, 4000, or 8000 ppm piperonyl butoxide (purity unspecified). Animals of the F0 generation, five weeks old at the start of the study, were mated for five days at nine weeks of age. Animals of the F1 generation was removed from their dams at four weeks of age and allocated randomly to continue treatment; the F2 generation was produced similarly to the F1 generation. Individual food intake was measured before mating and during mating, gestation, and lactation for all generations; litter size and weight and sex ratio were measured at birth, and pups were weighed 0, 4, 7, 14, and 21 days after birth. Some neurobehavioural tests were performed during lactation of the F2 generation and the results analysed on a litter basis. The tests included surface righting and negative geotaxis on postnatal days 4 and 7, cliff avoidance on postnatal day 7, swimming behaviour on postnatal days 4 and 14, and olfactory orientation on postnatal day 14. Food consumption was reduced by 4-44% in F0 animals at 8000 ppm except during mating, by 47% in F1 animals at 8000 ppm during lactation, and by 16-22% in F0 and F1 animals at 4000 ppm during lactation. The mean litter size of F1 animals at 8000 ppm was not significantly reduced (7.7; 10.6 in controls), but the mean F1 litter weight was reduced by 38% (statistically significant) at 8000 ppm and by 18% (not statistically significant) at 4000 ppm. F1 pups at 8000 ppm had a lower survival index at postnatal day 21 (63%; 91% in controls for males, statistically significant; 79%; 89% in controls for females, not statistically significant). The weights of all F1 pups were reduced, but there was no dose-response relationship at 1000-4000 ppm. The results of neurobehavioural tests for treated F1 animals were different from those of controls in some instances, but no dose-related response was evident. The mean F2 litter size was significantly reduced at 4000 ppm (10.3; 13.1 in controls) and 8000 ppm (7.0), and the mean F2 litter weights were reduced in all treated groups by 13-57%. F2 pups at 8000 ppm had a lower survival index than controls at postnatal day 21 (59% in males, statistically significant; 79% in females, not statistically significant), and F2 pup weights were reduced at 2000, 4000, and 8000 ppm. At 2000 and 4000 ppm, the effect was evident only from postnatal day 4; at 1000 ppm, reductions in pup weights were observed on postnatal day 4 in males and postnatal day 7 in animals of each sex. There was no NOAEL because of effects on pup weights at all doses (Tanaka et al., 1992). Groups of 10 male and 10 female Crj:CD-1 mice were fed diets containing 0,1500, 3000, or 6000 ppm piperonyl butoxide (purity unspecified) for four weeks before mating (F0 generation), during gestation, and until the F1 generation was eight weeks old. Open-field activity was measured in the F0 generation after three weeks of treatment. Litter size, pup weight, and some developmental behavioural signs (surface righting, negative geotaxis, cliff avoidance, swimming, and olfactory orientation) were measured during lactation of the F1 generation; open-field activity was measured at three and eight weeks of age and multiple water T-maze activity at six weeks of age. A dose-related decrease in ambulation and rearing was seen in the open-field test in males of the F0 generation, but only the former was statistically significant at the high dose. Pup body weight at birth was reduced in all groups; on postnatal day 21, the body weight of animals at the middle dose was 7% lower than that of controls, and that of animals at the high dose was 41% lower. The survival indexes at postnatal day 21 were 79, 93, 80, and 52 in controls and in mice at the low, middle, and high doses, respectively. The results of the behavioural test during lactation were not significant, except for reduced olfactory orientation in animals at the middle and high doses. The results of the open-field test and the multiple water T-maze test were not altered by treatment, except for a few, not dose-related differences in some parameters (Tanaka, 1992). Rats In a two-litter, two-generation study of reproductive toxicity, groups of 26 Sprague-Dawley CD rats of each sex, seven weeks of age, received piperonyl butoxide in the diet at 0, 300, 1000, or 5000 ppm, equal to 0, 20, 68, and 350 mg/kg bw per day for males (average food intake calculated in weeks 1-28 of the study) and to 0, 29, 94, and 480 mg/kg bw per day for females (calculated in weeks 1-12 of the study). The stability, homogeneity, and correspondence of the actual concentrations in the diets to the nominal concentrations were checked several times before and during the study and found to be acceptable. Rats were maintained on their respective diets for 85 days before mating, throughout the two mating periods, and until scheduled sacrifice. The F1b generation litters were weaned on day 21 post partum, and groups of 26 rats of each sex were selected to form the F1b adult generation. These animals were maintained on their respective diets for 83 days before mating. Animals were observed for signs of toxicity, and body weight and food consumption were recorded. External and internal gross examinations were performed on adult rats and on a selected number of weanlings; histopathological examination was undertaken for the reproductive tracts of control animals, those at the high dose, and those of rats at the low and middle doses that failed to mate successfully in either mating period. Clinical and pathological examinations showed no treatment-related toxic effects in adult F0 or F1b animals. The body weights of adult animals of each sex at 5000 ppm were lower than those of controls from a few weeks after the beginning to the end of the study. This effect occasionally corresponded to reduced food intake. Mating performance, fertility indexes, gestation indexes, length of gestation, and numbers of live and dead pups at birth were not affected by treatment. The viability and lactation indexes, clinical conditions, and pathological appearance of pups of all generations were also unaffected. The body weights of male and female pups of all generations at 5000 ppm were lower than those of control pups. This effect was not detectable at birth but was seen as early as day 4 post partum. The NOAEL for parental toxicity and pup development was 1000 ppm, equal to 68 mg/kg bw per day (Robinson et al., 1986). During the study of carcinogenicity reviewed above (Sarles & Vandergrift, 1952), rats of each sex were pair-caged throughout the experiment, except during nursing. No effect on reproductive efficiency was seen in the first, second, or third generations (no details given). (e) Developmental toxicity Mice Groups of 20 pregnant Crj:CD-1 mice were given piperonyl butoxide (purity, > 95%) in olive oil by gavage on day 9 of gestation at doses of 0, 1065, 1385, or 1800 mg/kg bw. Dams were weighed on gestation days 9 and 18 and then sacrificed, and the uteri were examined for the presence and position of resorption sites, fetuses, and implantation sites. Viable fetuses were weighed and examined for external malformations and variations, and then fixed and stained for visualization of the skeleton. No abnormal behaviour or mortality was observed in dams. One dam at the middle dose and two at the high dose aborted; the litters of one dam at the middle dose and three at the high dose were resorbed. Maternal body-weight gain was comparable in all groups. The total resorption rates were significantly greater at the middle (26%) and high (32%) doses than in controls (6%), probably due to total litter resorptions, since the number of viable fetuses per dam was comparable in all groups. (The raw data were not available to confirm the reviewer's hypothesis.) The average fetal body weight was significantly reduced in males, by 3% at the middle dose and 7% at the high dose, and in females, by 4% at the low dose, 5% at the middle dose, and 6% at the high dose. Exencephaly, craniochisis, open eyelids, omphalocele, kinky tail, and talipes varus were observed in all groups. Oligodactyly in the forelimbs was found in none of the controls but in one fetus at the low dose, four (2%) at the middle dose, and 27 (6%) at the high dose. A single oral dose > 1065 mg/kg bw per day of piperonyl butoxide to dams on day 9 of gestation was thus embryo- and fetotoxic (Tanaka et al., 1994). Rats Groups of 20 pregnant COBS random-bred albino rats were given 0, 300, or 1000 mg/kg bw per day piperonyl butoxide (technical-grade; purity unspecified) dissolved in corn oil by gavage on days 6-15 of gestation. The doses were chosen after a pilot study in which six animals per group were treated with 0, 100, 300, 1000, or 3000 mg/kg bw per day; reduced body-weight gain was observed during gestation days 6-15 at the highest dose. Pregnant animals were shipped from the breeder to the test laboratory on day 1 of gestation and were observed and weighed daily. On day 20 of gestation, they were sacrificed and the usual parameters were determined. No signs of toxicity were observed. Body-weight gain was reduced by 10% in animals at the low dose and by 15% in those at the high dose, mainly between days 15 and 20 of gestation. Reproductive parameters were not significantly affected by treatment. One female at 300 mg/kg bw resorbed 8 of 11 fetuses, and one at the high dose resorbed the entire litter. Fetuses of treated dams had no internal, external, or skeletal malformations that could be related to treatment. There was no NOAEL for maternal toxicity because of reduced body-weight gain at both doses. The NOAEL for embryo- and fetotoxicity was 1000 mg/kg bw per day on the basis of the absence of any significant finding (Kennedy et al., 1977). This report from Industrial Biotest Laboratories has not been validated by a governmental agency and was therefore not taken into account by the Meeting. Groups of 17-20 pregnant Wistar rats were given piperonyl butoxide (purity, 80%) at 0, 62.5, 125, 250, or 500 mg/kg bw dissolved in corn oil by gavage on days 6-15 of gestation. They were sacrificed on day 22 of gestation and necropsied, and their fetuses were removed and examined for external, visceral, and skeletal changes. There were no deaths or signs of toxicity in dams and no effect on the numbers of corpora lutea, live fetuses, resorption sites plus dead fetuses, anomalous fetuses, anomalous litters, or fetal body weight. The types and incidences of anomalies in the treated groups were comparable to those of the control group (data not shown). There was no evidence of embryotoxicity, fetotoxicity, or teratogenicity, and no maternal toxicity was elicited at the doses used (Khera et al., 1979). Groups of 20 timed-pregnant Sprague-Dawley CD rats were given undiluted piperonyl butoxide (purity, 90.78%) at 0, 200, 500, or 1000 mg/kg bw per day by gavage on days 6-15 of gestation. The doses were chosen in a preliminary pilot study in which five animals per group were treated with 0, 250, 500, 1000, 2000, or 4000 mg/kg bw per day, and in which all animals at 4000 and four-fifths of those at 2000 mg/kg bw per day groups died or became moribund. Animals were observed and weighed daily. On day 20 of gestation, they were sacrificed and the usual parameters plus liver weight were determined. No females aborted or delivered early, but wetness in the urogenital area was observed in 13/24 dams at the highest dose, and stains of urine, red urogenital discharge, and perinasal encrustation were seen at lower incidences. Body-weight gain was reduced between days 6 and 9 of gestation in animals at the low dose (an effect considered to be nonsignificant because of the low weight of non-pregnant animals) and between days 6 and 15 in animals at the middle and high doses; these reductions were associated with reduced food intake, resulting in a significantly lower body weight (by about 5%) in animals at 500 and 1000 mg/kg bw per day on days 15 and 18 of gestation. Increased absolute (by 8%) and relative (by 11%) weights were observed at the high dose. Reproductive parameters were not significantly affected by treatment. Fetuses of treated dams had no internal, external, or skeletal malformations that could be related to treatment. The NOAEL for maternal toxicity was 200 mg/kg bw per day on the basis of reduced body-weight gain and food consumption, increased liver weight, and signs of toxicity at higher doses. The NOAEL for embryo- and fetotoxicity was 1000 mg/kg bw per day on the basis of the absence of any significant finding (Chun & Neeper-Bradley, 1991). Rabbits In a range-finding study, five inseminated New Zealand white rabbits were treated by gavage with piperonyl butoxide during gestation days 7-19 at doses of 0, 50,100, 200, 300, or 400 mg/kg bw per day in corn oil. All animals except one control survived until the end of the study. Two animals each at 300 and 400 mg/kg bw per day and one at 100 mg/kg bw per day group aborted all or part of their litters between gestation days 22 and 26. Decreased defaecation was observed at the highest dose, and animals at the two highest doses were thinner than normal at the end of the treatment period. Significant reductions in body-weight gain and some body-weight loss were observed in rabbits at 300 and 400 mg/kg bw per day; a trivial reduction in body-weight gain was observed in animals at 200 mg/kg bw per day. No consistent effects were seen on uterine parameters. Doses of 50, 100, and 200 mg/kg bw per day were therefore chosen for the definitive study of teratogenicity. Groups of 16 inseminated New Zealand white rabbits were treated by gavage with piperonyl butoxide (purity, 100%) during gestation days 7-19 at doses of 0, 50, 100, or 200 mg/kg bw per day in 0.5 ml/kg bw corn oil. Caesarean sections were performed on gestation day 29, and the fetuses were removed for teratological evaluation. All animals survived until the end of the study. Decreased defaecation was observed in animals at 100 and 200 mg/kg bw per day. Slight body-weight loss was observed at the middle and high doses during the treatment period, but there was substantial recovery of body weight during the post-treatment period, so that the weight gain during the overall gestation period was comparable to that of controls. The mean post-implantation losses of treated does were slightly greater than those of controls but were not dose-related. Malformations were observed incidentally and were considered to be unrelated to treatment. The numbers of fetuses with more full ribs than normal (45, 58, 59, and 60% at 0, 50, 100, and 200 mg/kg bw, respectively) or with 27 presacral vertebrae (20, 32, 27, and 40%, respectively) were greater than those in controls, but the number of litters was not different. There was no clear dose-effect relationship, and the relevance of this finding is dubious. The NOAEL for maternal toxicity was 50 mg/kg bw per day on the basis of decreased defaecation and dose-related body-weight losses during the treatment period. The NOAEL for teratogenicity was 200 mg/kg bw per day (Leng et al., 1986). The 1992 JMPR wrongly reported an NOAEL of 100 mg/kg bw per day. (f) Genotoxicity The results of studies of the genotoxicity of piperonyl butoxide are reported in Table 2. (g) Special studies (i) Dermal and ocular irritation and dermal sensitization Piperonyl butoxide was applied at 0.5 ml to intact, clipped skin of six New Zealand white rabbits for 4 h under a semi-occlusive dressing, and the treated areas were examined for erythema and oedema up to 78 h after the contact period. An adjacent area of untreated skin served as the control. Piperonyl butoxide was very mildly irritating (Romanelli, 1991a). An older study reported similar results (Sarles et al., 1949). Piperonyl butoxide at 0.1 ml was instilled into the conjuntival sac of one eye of six New Zealand white rabbits, and the treated eyes were examined up 72 h after instillation. Conjunctival irritation was observed, which fully recovered within 72 h. No corneal or iridal lesions were observed (Romanelli, 1991b). An older study reported similar results in rabbits, cats, and dogs (Sarles et al., 1949). Table 2. Results of tests for the genotoxicity of piperonyl butoxide End-point Test system Concentration Purity Results Reference or dose (%) In vitro Reverse mutation S. typhimurium TA98, TA100, 100-5000 µg/plate 90.78 Negativea Lawlor (1991) TA1535, TA1537, TA1538 Reverse mutation S. typhimurium TA98, NR NR Negative White et al. (1977) TA 100, TA1537 Reverse mutation E. coli WP2 1 mg/disc 80 Negative Ashwood-Smith et al. (1972) Gene mutation Mouse lymphoma L5178Y 6.3-100 µg/mlb NR Positive McGregor et al. cells (1988) Gene mutation Chinese hamster ovary, cells 10-100 µg/mlc NR Equivocal Tu et al. (1985) 25-500 µg/mld Negative Unscheduled DNA Rat hepatocytes 1-100 µg/mle 90.78 Negative McKeon & Phil synthesis (1991) Unscheduled DNA Human liver slices 0.05-2.5 mmol/litre 90.78 Negative Lake (1995) synthesis Chromosomal Chinese hamster ovary cells 25-99.9 µg/ml 90.78 Negativea Murli (1991) aberration 62.6-251 µg/mla Table 2. (cont'd). End-point Test system Concentration Purity Results Reference or dose (%) In vivo Dominant lethal ICR/Ha Swiss mice 0, 200, or 1000 mg Commercial Equivocal Epstein et al. (1972) mutation intraperitoneally or formulation 1000 mg/kg bw orally × 5 NR, not reported a With and without metabolic activation b Lethal at 100 µg/ml c Without metabolic activation; cytotoxic at > 30 µg/ml d With metabolic activation; cytotoxic at > 300 µg/ml e Cytotoxic at > 49.9 µg/ml Skin sensitization was studied in 10 male Hartley guinea-pigs by a modified Buehler method. A gauze patch containing 0.4 ml piperonyl butoxide was applied for 6 h onto clipped skin, three times a week for three weeks. After a two-week rest period, the animals were challenged on another site with a single 6-h application. Chlorodinitrobenzene (0.1% w/v in a 50% ethanol:0.9% saline solution) was used as the positive control. No evidence of contact sensitization was observed (Romanelli, 1991c). An older study also reported no response in rabbits (Sarles et al., 1949) (ii) Studies with mixtures Neonatal ICR/Ha Swiss mice (n = 91) were given subcutaneous injections of 5 mg piperonyl butoxide alone at the ages of one and seven days and 10 mg at the ages of 14 and 21 days. Further groups were given the same doses in combination with Freon-112 (n = 137) or -113 (n = 94) at doses of 10 mg at one and seven days and 20 mg at 14 and 21 days. Control animals were treated with the solvent, tricaprylin. All surviving animals were killed after 52 weeks. No tumours were found in animals treated with piperonyl butoxide, but the incidence of hepatomas in male mice given piperonyl butoxide plus Freon was significantly increased when compared with that in groups receiving solvent, piperonyl butoxide, or Freon alone (Epstein et al., 1967). Groups of 45 Sprague-Dawley CD rats of each sex were fed either standard diets or diets containing 400 ppm pyrethrins plus 2000 ppm piperonyl butoxide for 104 weeks. The diets were prepared daily from a 10-fold concentrated pre-mix prepared freshly once a week. The purity of piperonyl butoxide was 90.5%, and that of pyrethrins was 53.1% (batch used until week 55) or 52.4% (batch used from week 56 until termination); the diets were prepared taking into account the purity of the compounds. The actual concentrations and the stability of the diet were not tested. Body weight and food consumption were determined once a week. The average daily intakes were 79 and 101 mg/kg bw piperonyl butoxide and 16 and 20 mg/kg bw pyrethrins for males and females, respectively. Animals were observed for clinical signs, skin lesions, and palpable masses. All animals found dead or moribund were inspected, and macroscopic lesions were examined microscopically. During week 101, urinalysis and haematological and clinical chemical tests were performed in 10 animals per group. At termination, all animals were observed grossly and selected organs were examined microscopically. No treatment-related clinical signs of toxicity were observed. Mortality was 84 and 76% in control males and females and 80 and 58% in treated males and females, respectively. The body weights of treated females were about 20% lower than those of controls, mainly during the first 78 weeks, while at termination treated animals were about 10% lighter than controls; the difference was less evident (about 5%) in males. Slightly reduced food intake was also observed until week 27 of treatment. Haematological, clinical chemical, and urinary parameters were not significantly altered in treated animals, and macroscopic and microscopic examinations revealed no significant treatment-related neoplastic or non-neoplastic effects (Hunter et al., 1977). 3. Observations in humans In nine men, antipyrine metabolism was not affected by a single oral dose of 50 mg (0.71 mg/kg bw) piperonyl butoxide (Conney et al., 1972). Two male infants, whose mothers were sisters and who were born within two weeks of each other, had coarctation of the aorta. Exposure to insect repellents and insecticides, including piperonyl butoxide, during week 8 of gestation was reported (Hall et al., 1975). Percutaneous absorption of pyrethrin and piperonyl butoxide was studied in six male volunteers. A formulation containing 0.3% pyrethin and 3.0% piperonyl butoxide was spread on the ventral forearm for 30 min. This formulation was chosen because it corresponds to that of a commercially available product used for the treatment of head lice. The formulation contained either 14C-pyrethrin or 14C-piperonyl butoxide. After application, urine was collected for up to seven days, and percutaneous absorption was determined from total urinary excretion of radioabel, assuming that 22.5% of pyrethin and 51.3% of piperonyl butoxide are excreted in the urine after parenteral injection, as was shown in monkeys. Absorption of pyrethrin was 1.9 ± 1.2% and that of piperonyl butoxide 2.1 ± 0.6% of the administered dose. No radiolabel was found in blood taken 1 h after application. The extrapolated absorption from human scalp was 7.5 ± 4.7% of pyrethin and 8.3 ± 2.4% of piperonyl butoxide (Wester et al., 1994). Comments Piperonyl butoxide is metabolized by oxidation of the methylene group of the methylenedioxyphenyl moiety to yield carbon dioxide. The remainder of the molecule undergoes further degradation and is excreted mainly in the urine. As it is an alternative substrate (and therefore a competitive inhibitor) for the microsomal cytochrome P450 system, piperonyl butoxide inhibits the metabolism of several drugs and pesticides. The mechanism of action of this inhibition has been elucidated in several studies. In male rats given single oral doses of about 500 mg/kg bw of [methylene-alpha 14C]-piperonyl butoxide, the label reached a peak in blood after 3-12 h and dropped by about 50% within 24 h. The highest levels of radiolabel were found in the gastrointestinal tract and its, contents, suggesting that enterohepatic circulation occurs. High levels of radioactivity were also found in the lung, liver, kidney, fat, prostate, and seminal vesicles. The excretion pattern was unchanged after 14 repeated doses of piperonyl butoxide. Piperonyl butoxide has negligible acute toxicity, and it has been classified by WHO as unlikely to present an acute hazard in normal use. Both short-term and long-term studies show that the target organ of the toxicity of piperonyl butoxide is the liver. Male animals were slightly more sensitive than females. In a number of short-term studies in rodents, hepatic toxicity was characterized by liver enlargement with associated hypertrophic hepatocytes, focal necrosis, and, at times, alteration of some clinical chemical parameters. The NOAEL for liver toxicity was about 100 mg/kg bw per day. In rats exposed to piperonyl butoxide by inhalation at 0, 15, 74, 155, or 512 mg/m3 for 6 h per day on five days a week for 13 weeks, effects were seen on the liver at the highest dose. Irritation of the upper airways was seen at all doses, with squamous metaplasia of the larynx. In a one-year study in dogs fed diets containing 0, 100, 600, or 2000 ppm piperonyl butoxide, reduced body-weight gain, increased liver weight with hypertrophic hepatocytes, and alteration of some clinical chemical parameters were observed at 2000 ppm. The NOAEL in this study was 600 ppm, equal to 16 mg/kg bw per day. Several studies have been conducted of carcinogenicity in mice and rats, some of which were considered to be inadequate. In a 112-week study, mice were given diets containing 5000 or 10 000 ppm piperonyl butoxide during weeks 1-30 and 500 or 2000 ppm during weeks 31-112. No increase in tumour incidence was observed. Mice were fed diets that gave a daily intake of 0, 30, 100, or 300 mg/kg bw for 78 weeks. Eosinophilic foci and adenomas with eosinophilic cells were observed more frequently in the livers of males at the middle dose and males and females at the high dose. The NOAEL in this study was 30 mg/kg bw per day on the basis of effects on the liver. In a 12-month study of carcinogenicity in the liver, male mice were fed diets containing 0, 6000, or 12 000 ppm piperonyl butoxide. Body weights were reduced in a dose-related manner, and increased mortality was observed in animals at the high dose. Hepatocellular adenomas and carcinomas were observed in treated groups. Piperonyl butoxide was carcinogenic at doses that were toxic to the liver and caused general toxicity. In a two-year study in rats at dietary concentrations adjusted to achieve doses of 0, 30, 100, or 500 mg/kg bw per day, increased liver weights, with corresponding hyperplasia and hypertrophy of hepatocytes, morphological changes, and lesions in the endocrine and hormone-sensitive organs, were observed at 100 and 500 mg/kg bw per day. These effects were considered to be secondary to the ability of piperonyl butoxide to induce hepatic cytochrome P450 enzymes. Piperonyl butoxide was not found to be carcinogenic in this study. After reconsideration of the data on testes in this study, previously evaluated by the 1992 JMPR, and taking into account the results of other long-term studies, the Meeting concluded that the NOAEL was 30 mg/kg bw per day on the basis of effects on the liver. Two studies of carcinogenicity were conducted in rats fed diets containing 0, 5000, or 10 000 ppm piperonyl butoxide. No significantly increased incidence of neoplasia was found in treated rats. Effects on body weight and mortality were observed at the highest dose. In one study, ileocaecal lesions were observed in both groups. Another study of carcinogenicity was conducted in rats fed diets containing 0, 6000, 12 000, or 24 000 ppm. Increased mortality was observed in females at the middle dose. Absolute liver weights were increased in females at the low dose and in animals of each sex at the high dose. Nodular lesions of the liver were observed in treated animals, and their incidence and severity were related to the dose. Hepatocellular adenomas and carcinomas were observed in animals at the middle and high doses. Gastric and caecal haemorrhages, renal lesions, anaemia, and platelet alteration were observed in treated animals. Piperonyl butoxide was carcinogenic at doses that caused general toxicity. In a 104-week study in rats, piperonyl butoxide was given at 2000 ppm in the diet in combination with pyrethrins at 400 ppm. A slight reduction in the body weights of treated females was the only adverse effect observed. A two-generation study of reproductive toxicity, with one litter per generation, was conducted in mice fed diets containing 0, 1000, 2000, 4000, or 8000 ppm piperonyl butoxide. There was no NOAEL because of reduced pup weight at all doses. Pup viability was reduced at the highest dose. In a two-litter, two-generation study of reproductive toxicity in rats at dietary levels of 0, 300, 1000, or 5000 ppm, the NOAEL for parental toxicity and pup development was 1000 ppm (equal to 68 mg/kg bw per day) on the basis of lowered body weight at 5000 ppm. Embryo- and fetotoxicity were observed when mice were given single doses of piperonyl butoxide at 0, 1070, 1390, or 1800 mg/kg bw by gavage on day 9 of gestation. Piperonyl butoxide was not embryotoxic or teratogenic in rats or rabbits. Maternal toxicity was found in rats at doses > 500 mg/kg bw per day. The NOAEL was 200 mg/kg bw per day in a study of developmental toxicity in rabbits given 0, 50, 100, or 200 mg/kg bw per day by gavage. The incidence of common developmental variations, such as more full ribs and more than 27 presacral vertebrae, was increased in all treated groups. Since a clear dose-effect relationship was lacking, the association of this finding with treatment was considered dubious. The NOAEL for maternal toxicity was 50 mg/kg bw per day. Piperonyl butoxide was a mild dermal and ocular irritant but not a dermal sensitizer in rabbits. Piperonyl butoxide was adequately tested for genotoxicity in a range of assays in vivo and in vitro. The Meeting concluded that it is not genotoxic. A single dose of 0.71 mg/kg bw piperonyl butoxide did not alter antipyrine metabolism in humans. A study in which a formulation containing 3% piperonyl butoxide was spread onto the ventral forearm of adult male volunteers indicated that about 8% of the applied dose would be absorbed through the human scalp. These data did not contribute directly to the establishment of the ADI. An ADI of 0-0.2 mg/kg bw was established on the basis of the NOAEL of 600 ppm (equal to 16 mg/kg bw per day) in the one-year study in dogs, with a 100-fold safety factor. Toxicological evaluation Levels that cause no toxic effect Mouse: 30 mg/kg bw per day (78-week dietary study of toxicity and carcinogenicity) Rat: 30 mg/kg bw per day (two-year dietary study of carcinogenicity) 200 mg/kg bw per day (maternal toxicity in study of developmental toxicity) 500 mg/kg bw per day (embryo- and fetotoxicity in study of developmental toxicity) 1000 ppm, equal to 68 mg/kg bw per day (study of reproductive toxicity) Rabbit: 50 mg/kg bw per day (study of developmental toxicity) 200 mg/kg bw per day (embryo- and fetotoxicity and teratogenicity in study of developmental toxicity) Dog: 600 ppm, equal to 16 mg/kg bw per day (one-year study of toxicity) Estimate of acceptable daily intake for humans 0-0.2 mg/kg bw Studies that would provide information useful for continued evaluation of the compound 1. Further observations in humans 2. Short-term studies with mixtures of piperonyl butoxide and other active ingredients, in ratios relevant to human exposure Toxicological criteria for setting guidance values for dietary and non-dietary exposure to piperonyl butoxide Exposure Relevant route, study type, species Results, remarks Short-term (1-7 days) Skin, irritation, rabbit Mildly irritating Eye, irritation, rabbit Irritating Skin, sensitization, guinea-pig Not sensitizing Inhalation, lethality, rat Lacrimation, salivation, nasal discharge, and laboured breathing at 5.9 mg/litre for 4 h. No mortality Oral, lethality, mouse, rat, cat, dog LD50 = 4-14 g/kg bw Dermal, lethality, rabbit LD50 > 2 g/kg bw Medium-term (1-26 weeks) Repeated oral, toxicity, mice, rats, NOAEL = 100 mg/kg bw per day; effects on 3-13 weeks liver Repeated inhalation, toxicity, rats, 13 weeks Irritating to upper airways at 15 mg/m3 for 6 h per day, 5 days per week, with squamous metaplasia of the larynx; effects on the liver at 512 mg/m3 Oral, developmental toxicity, rabbit NOAEL = 50 mg/kg bw per day for maternal toxicity; no fetotoxicity or teratogenidty Oral, reproductive toxicity, rat NOAEL = 68 mg/kg bw per day; maternal and pup toxicity Long-term (> one year) Repeated oral, toxicity, dog, one year NOAEL = 16 mg/kg bw per day References Ashwood-Smith, M.J., Trevino, J. & Ring, R. (1972) Mutagenicity of dichlorvos. Nature, 240, 418-420. Brady, J.T., Montelius, D.A., Beierschmitt, W.P., Wyand, D.S., Khairalla, E.A. & Cohen, S.D. (1988) Effect of piperonyl butoxide post-treatment on acetaminophen hepatotoxicity. Biochem. Pharmacol., 37, 2097-2099. Cardy, R.H., Renne, R.A., Warner, J.W. & Cypher, R.L. (1979) Carcinogenesis bioassay of technical-grade piperonyl butoxide in F344 rats. J. Natl Cancer Inst., 62, 569-578. Chun, J.S. & Neeper-Bradley, T.L. (1991) Developmental toxicity evaluation of piperonyl butoxide administered by gavage to CD (Sprague-Dawley) rats. Unpublished report No. 54-586 from Bushy Run Research Center, Export, Pennsylvania, USA. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Conney, A.H., Chang, R., Levin, W.M., Garbut, A., Munro-Faure, A.D., Peck, A.W. & Bye, A. (1972) Effects of piperonyl butoxide on drug metabolism in rodents and man. Arch. Environ. Health, 24, 97-106. Dalvi, R.R. & Dalvi P.S. (1991) Differences in the effects of piperine and piperonyl butoxide on hepatic drug-metabolizing enzyme system in rats. Drug Chem. Toxicol., 14, 219-229. Epstein, S.S., Joshi, S., Andrea, J., Clapp, P., Falk, H. & Mantel, N. (1967) Synergistic toxicity and carcinogenicity of 'Freons' and piperonyl butoxide. Nature, 214, 526-528. Epstein, S.S., Arnold, E., Andrea, J., Bass, W. & Bishop, Y. (1972) Detection of chemical mutagens by the dominant lethal assay in the mouse. Toxicol. Appl. Pharmacol., 233, 288-325. Fishbein, L., Falk, H.L., Fawker, J., Jordan, S. & Corbett, B. (1969) The metabolism of piperonyl butoxide in the rat with 14C in the methylenedioxy or alpha-methylene group. J. Chromatogr., 41, 61-79. Franklin, M.R. (1972) Inhibition of hepatic oxidative xenobiotic metabolism by piperonyl butoxide. Biochem. Pharmacol., 21, 3287-3299. Fujitani, T., Ando, H., Fujitani, K., Ikeda, T., Kojima, A., Kubo, Y., Ogato, A., Oishi, S., Takahashi, O. & Yoneyama, M. (1992) Sub-acute toxicity of piperonyl butoxide in F344 rats. Toxicology, 72, 291-298. Fujitani, T., Tanaka, T., Hashimoto, Y. & Yoneyama, M. (1993a) Subacute toxicity of piperonyl butoxide in ICR mice. Toxicology, 83, 93-100. Fujitani, T., Tada, Y. & Yoneyama, M. (1993b) Hepatotoxicity of piperonyl butoxide in male F344 rats. Toxicology, 84, 171-183. Gabriel, D. (1991a) Acute oral toxicity, LD50-rats. Unpublished report No. 91-7317A from Biosearch Inc., Philadelphia, Pennsylvania, USA. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Gabriel, D. (1991b) Acute dermal toxicity, single level-rabbits. Unpublished report No. 91-7317A from Biosearch Inc., Philadelphia, Pennsylvania, USA. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Goldenthal, E.I. (1993a) Evaluation of piperonyl butoxide in an eight week toxicity study in dogs. Unpublished report No. 542-004 from International Research and Development Corp., Mattawan, Michigan, USA. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Goldenthal, E.I. (1993b) Evaluation of piperonyl butoxide in a one year chronic dietary toxicity study in dogs. Unpublished report No. 542-005 from International Research and Development Corporation, Mattawan, Michigan, USA. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Goldstein, J.A., Hickman, P. & Kimbrough R.D. (1973) Effects of purified and technical piperonyl butoxide on drug metabolizing enzymes and ultrastructure of rat liver. Toxicol. Appl. Pharmacol., 26, 444-458. Graham, C (1987) 24-Month dietary toxicity and carcinogenicity study of piperonyl butoxide in the albino rat. Unpublished report No. 81690 from Bio-Research Ltd Laboratory, Seneville, Quebec, Canada. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Hall J.G., McLaughlin, J.F. & Stamm, S. (1975) Coarctation of the aorta in male cousins with similar maternal environmental exposure to insect repellent and insecticides. Pediatrics, 55, 425-427. Hermanski, S.J. & Wagner, C.L. (1993) Chronic dietary oncogenicity study with piperonyl butoxide in CD-1 mice. Unpublished report No. 91N0134 from Bushy Run Research Center, Export, Pennsylvania, USA. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Hoffman, G.M. (1991) An acute inhalation toxicity study of piperonyl butoxide in the rat. Unpublished report No. 91-8330 from Bio/dynamics, East Millstone, New Jersey, USA. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Hunter, B., Bridges, J.L. & Prentice, D.E. (1977) Long term feeding of pyrethrins and piperonyl butoxide to rats. Unpublished report from Huntington Research Centre, Huntington, Cambs, United Kingdom. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Innes, J.R.M., Ulland, B.M., Valerio, M.G., Petrucelli, L., Fishbein, L., Hart, E.R., Bates, R.R., Falk, H.L., Gart, J.J., Klein, M., Mitchell, I. & Peters, J. (1969) Bioassay of pesticides and industrial chemicals for tumorigenicity in mice: a preliminary note. J. Natl Cancer Inst., 42, 1101-1114. Jaffe, H., Fuji, K., Guerin, H., Sengupta, M. & Epstein, S.S. (1968) In vivo inhibition of mouse liver microsomal hydroxylating systems by methylenedioxyphenyl insecticidal synergists and related compounds. Life Sci., 7, 1051-1062. Jaffe, H., Fuji, K., Guerin, H., Sengupta, M. & Epstein, S.S. (1969) Bi-modal effect of piperonyl butoxide on the o- and p-hydroxylations of biphenyl by mouse liver microsomes. Biochem. Pharmacol., 18, 1045-1051. Kamienski, F.X. & Casida, J.E. (1970) Importance of demethylenation in the metabolism in vivo and in vitro of methylenedioxyphenyl synergists and related compounds in mammals. Biochem. Pharmacol., 19, 91-112. Kennedy, G.L., Smith, S.H., Kinoshita, F.K., Keplinger, M.L. & Calandra, J.C. (1977) Teratogenic evaluation of piperonyl butoxide in the rat. Food Cosmet. Toxicol., 15, 337-339. Khera, K.S., Whalen, C., Angers, G. & Trivett, G. (1979) Assessment of the teratogenic potential of piperonyl butoxide, biphenyl, and phosalone in the rat. Toxicol. Appl. Pharmacol., 47, 353-358. Lake, B.G. (1995) An investigation of the effect of piperonyl butoxide on unscheduled DNA synthesis in cultured human liver slices. Unpublished report No. 1501/1 from BIBRA International, Carshalton, Surrey, United Kingdom. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Lawlor, T.E. (1991) Piperonyl butoxide in the Salmonella/mammalian- microsome reverse mutation assay (Ames test) with a confirmatory assay. Unpublished report No. 14413-0-401R from Hazleton Washington, Kensington, Maryland, USA. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Lehman, A.J. (1948) Q. Bull. Assoc. Food Drug Off., 12, 82. Lehman, A.J. (1951) Q. Bull. Assoc. Food Drug Off., 15, 122. Lehman, A.J. (1952a) Q. Bull. Assoc. Food Drug Off., 16, 43. Lehman, A.J. (1952b) Q. Bull. Assoc. Food Drug Off., 16, 47. Leng, J.M., Schwartz, C.A. & Schardein, J.L. (1986) Teratology study in rabbits. Unpublished report No. 542-002 from International Research and Development Corp., Mattawan, Michigan, USA. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Levine, B.S. & Murphy, S.D. (1977a) Esterase inhibition and reactivation in relation to piperonyl butoxide-phosphorothionate interactions. Toxicol. Appl. Pharmacol., 40, 379-391. Levine, B.S. & Murphy, S.D. (1977b) Effect of piperonyl butoxide on the metabolism of dimethyl and diethyl phosphorothionate insecticides. Toxicol. Appl. Pharmacol., 40, 393-406. Maekawa, A., Onodera, H., Furuta, K., Tanigawa, H., Ogiu, T. & Hayashi, Y. (1985) Lack of evidence of carcinogenicity of technical-grade piperonyl butoxide in F344 rats: Selective induction of ileocaecal ulcers. Food Chem. Toxicol., 7, 675-682. McGregor, D.B., Brown, A., Cattanach, P., Edwards, I., McBride, D., Riach, C. & Caspary, W.J. (1988) Responses of the L5178Y tk+/tk- mouse lymphoma cell forward mutation assay. III. 72 coded chemicals. Environ. Mol. Mutag., 12, 85-154. McKeon, M.E. & Phil, M. (1991) Piperonyl butoxide in the assay for unscheduled DNA synthesis in rat liver primary cell cultures with a confirmatory assay. Unpublished report No. 14413-O-447R from Hazleton Washington, Kensington, Maryland, USA. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Mirer, F.E., Levine, B.S. & Murphy, S.D. (1977) Parathion and methyl parathion toxicity and metabolism in piperonyl butoxide and diethyl maleate pretreated mice. Chem.-Biol. Interactions, 17, 99-112. Modeweg-Hansen, L., Lalande, M., Bier, C., Losos, G. & Osborne, B.E. (1984) A dietary dose range-finding study of piperonyl butoxide in the albino rat. Unpublished report No. 81802B from Bio-Research Laboratories, Edgewater, Maryland, USA. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Murli, H. (1991) Piperonyl butoxide: Measuring chromosomal aberrations in Chinese hamster ovary (CHO) cells with multiple harvests under conditions of metabolic activation. Unpublished report No. 14413-0-437C from Hazleton Washington, Kensington, Maryland, USA. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Negherbon, W.O. (1959) Handbook of Toxicology, Vol. 3, Philadelphia, Saunders. Newton, P.E. (1992) A subchronic (3-month) inhalation toxicity study of piperonyl butoxide in the rat via whole-body exposures. Unpublished report No. 91-8333 from Bio/dynamics, East Millstone, New Jersey, USA. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Phillips, J.C., Cunninghame, M.E., Price, R.J., Osimitz, T., Ganriel, K.L., Preiss, F.J., Butler, W.H. & Lake, B.G. (1995) Effect of piperonyl butoxide (PBO) on cell replication and xenobiotic metabolism in mouse liver (Abstract). Toxicologist, 15, 230. Robinson, K., Pinsonneault, L. & Procter, B.G. (1986) A two-generation (two-litter) reproduction study of piperonyl butoxide administered in the diet to the rat. Unpublished report No. 81689 from Bio-Research Laboratories Ltd, Montreal, Quebec, Canada. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Romanelli, P. (1991a) Primary skin irritation-rabbits. Unpublished report No. 91-7317A from Biosearch Inc., Philadelphia, Pennsylvania, USA. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Romanelli, P. (1991b) Primary eye irritation-rabbits. Unpublished report No. 91-7317A from Biosearch Inc., Philadelphia, Pennsylvania, USA. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Romanelli, P. (1991c) Guinea pig dermal sensitization-modified Buehler method. Unpublished report No. 91-7317A from Biosearch Inc., Philadelphia, Pennsylvania, USA. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Sarles, M.P. & Vandegrift, W.B. (1952) Chronic oral toxicity and related studies on animals with the insecticide and pyrethrum synergist, piperonyl butoxide. Am. J. Trop. Med. Hyg., 1, 862-883. Sarles, M.P., Dove, W.E. & Moore, D.H. (1949) Acute toxicity and irritation tests on animals with the new insecticide, piperonyl butoxide. Am J. Trop. Med., 29, 151-166. Schuller, H.M. & McMahon, J.B. (1985) Inhibition of N-nitroso- diethylamine-induced respiratory tract carcinogenesis by piperonylbutoxide in hamsters. Cancer Res., 45, 2807-2812. Selim, S. (1985) Single and repeated oral dose pharmacokinetic and distribution studies of piperonyl butoxide. Unpublished report No. WP509070/1 from Biological Test Center, Irvine, California, USA. Submitted to WHO by Endura SA. Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. Skrinijaric-Spoljar, M., Matthews, H.B., Engel, J.L. & Casida, J.E. (1971) Response of hepatic microsomal mixed-function oxidases to various types of insecticide chemical synergists administered to mice. Biochem. Pharmacol., 20, 1607-1618. Takahashi, O., Oishi, T., Fujitani, T., Tanaka, T. & Yoneyama, M. (1994a) Piperonyl butoxide induces hepatocellular carcinoma in male CD-1 mice. Arch. Toxicol., 68, 467-469. Takahashi, O., Oishi, T., Fujitani, T., Tanaka, T. & Yoneyama, M. (1994b) Chronic toxicity studies of piperonyl butoxide in F344 rats: Induction of hepatocellular carcinoma. Fundam. Appl. Toxicol., 22, 293-303. Tanaka, T. (1992) Effects of piperonyl butoxide on F1 generation mice. Toxicol. Lett., 60, 83-90. Tanaka, T. (1993) Behavioural effects of piperonyl butoxide in male mice. Toxicol. Lett., 69, 155-161. Tanaka, T., Takahashi, O. & Oishi, S. (1992) Reproductive and neurobehavioural effects in three-generation toxicity study of piperonyl butoxide administered to mice. Food Chem. Toxicol., 30, 1015-1019. Tanaka, T., Fujitani, T., Takahashi, O. & Oishi, S. (1994) Developmental toxicity evaluation of piperonyl butoxide in CD-1 mice. Toxicol. Lett., 71, 123-129. Tu, A.S., Coombes-Hallowell, W.E., Pallotta, S.L. & Catanzano, A. (1985) Evaluation of piperonyl butoxide in the CHO/HGPRT mutation assay with and without metabolic activation. Unpublished report No. 53906 from Arthur D. Little, Inc., Cambridge, Massachusetts, USA. Submitted to WHO by Endura SA, Bologna, Italy, for the Piperonyl Butoxide Task Force, Washington DC, USA. US National Cancer Institute (1979) Bioassay of piperonyl butoxide for possible carcinogenicity (DHEW Publ. No. 79-1375), Bethesda, Maryland, USA, US Department of Health, Education, and Welfare. Wester, R.C., Bucks, D.A.W. & Maibach, H.I. (1994) Human in vivo percutaneous absorption of pyrethrin and piperonyl butoxide. Food Chem. Toxicol., 32, 51-53. White, T.J., Goodman, D., Shulgin, A.T., Castagnoli, N., Lee, R. & Petrakis, N.L. (1977) Mutagenic activity of some centrally active aromatic amines in Salmonella typhimurium. Mutat. Res., 56, 199-202.
See Also: Toxicological Abbreviations Piperonyl butoxide (ICSC) Piperonyl Butoxide (FAO Meeting Report PL/1965/10/1) Piperonyl butoxide (FAO/PL:CP/15) Piperonyl butoxide (FAO/PL:1967/M/11/1) Piperonyl Butoxide (FAO/PL:1969/M/17/1) Piperonyl butoxide (WHO Pesticide Residues Series 2) Piperonyl butoxide (Pesticide residues in food: 1992 evaluations Part II Toxicology) Piperonyl Butoxide (IARC Summary & Evaluation, Volume 30, 1983)